Previsión
El precio objetivo medio de los analistas es de 4,56 € (+300,00 %). La mediana es de 4,56 € (+300,00 %).
| Comprar |
7 |
| Mantener |
1 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Neuronetics reports Q2 2026 revenue growth, narrows guidance and advances toward profitability
Neuronetics posted Q2 revenue of $41.6 million, up ~9% year-over-year, driven by Greenbrook clinics ($26.9 million, +16.8%) while NeuroStar revenue declined to $14.7 million as the company shifts customers from a session model toward capital sales and leasing. Gross margin improved to 51.1% and adjusted EBITDA was positive $0.3 million, with net loss narrowing to $3.4 million; cash totaled $25 million at quarter end after $7.6 million raised via an ATM. Management narrowed full-year revenue guidance to $160–164 million, lowered OPEX guidance and expects reduced cash burn as it scales Greenbrook, rolls out new NeuroStar commercial options and pursues interventional psychiatry opportunities. » Más en finance.yahoo.com
Neuronetics: stock jumps after strong quarterly results and turnaround hopes
For Q2 2026 Neuronetics reported revenue of $41.6 million (+9.1% y/y) and a net loss of $3.4 million (‑$0.05 per share), markedly better than the consensus estimate of about ‑$0.12. The clinic segment Greenbrook contributed $26.9 million (+16.8%) and was a key driver of growth; adjusted EBITDA improved to $0.3 million versus ‑$5.6 million a year earlier, and the cash outflow from operating and investing activities fell to $1.4 million. Management changes, including a new CFO, boosted confidence in the turnaround strategy, after which the stock rose about 24% in premarket trading. » Más en de.investing.com
Neuronetics amends adviser agreement for interim principal financial and accounting officer and raises monthly compensation
Neuronetics has revised the adviser agreement with interim Principal Financial and Accounting Officer Francis X. Brown III effective May 18, 2026; Brown will remain in office until a full-time controller and head of finance is appointed or until a mutually agreed written date. Compensation was adjusted from $25,000 to a monthly flat fee of $26,000. The company also reported Q1 2026 revenue of $34.5 million (above analyst expectations) but missed the EPS target; Neuronetics announced a partnership with ANT Neuro to integrate neuronavigation technology. » Más en de.investing.com
Neuronetics integrates ANT Neuro neuronavigation into NeuroStar system
Neuronetics is partnering with ANT Neuro to integrate the FDA-cleared neuronavigation system visor2 into the NeuroStar Advanced Therapy System for TMS. The technology provides real-time tracking and patient-specific 3D visualization to improve positioning, consistency and safety of treatments. The partnership will be presented later in May at the American Psychiatric Association annual meeting and in June at the Clinical TMS Society; a broader market rollout is planned for the second half of 2026. Neuronetics operates Greenbrook TMS centers, has a market capitalization of $105 million and has recently faced a steep share-price decline despite revenue growth. » Más en de.investing.com
Neuronetics increases revenue but misses EPS target in Q1 2026
Neuronetics reported Q1 2026 revenue of $34.5 million (+8% YoY), slightly above expectations, while EPS of -$0.16 missed the forecast of -$0.13. U.S. clinic revenues rose 15%, the NeuroStar segment fell 3%. Gross margin declined 230 basis points to 46.9%, operating expenses fell 6%, and net loss narrowed to $10.8 million. The company reaffirmed full-year guidance of $160–166 million, expects improved operating cash flow, and plans annual cost savings of $2.5–3.0 million; the stock rose 2.5% premarket. » Más en de.investing.com
Datos financieros
En el último trimestre, NEURONETICS INC. DL-,01 tuvo unos ingresos de 37,05 M € y un beneficio neto de -1,49 M €
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 37,05 M | 16,56 % |
| Beneficio bruto | 19,33 M | 32,56 % |
| Beneficio neto | -1,49 M | 80,62 % |
| EBITDA | 1,13 M | 120,66 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 88,55 M € |
Número de acciones | 77,73 M |
Máximo/mínimo de 52 semanas | 3,14 € - 0,73 € |
| Dividendos | No |
Beta | 1,20 |
Ratio P/E | -3,88 |
Ratio PEG | -0,04 |
Ratio P/B | 5,15 |
Ratio P/S | 0,61 |
Perfil de la empresa
Neuronetics, Inc., una empresa de tecnología médica en fase comercial, diseña, desarrolla y comercializa productos para pacientes con trastornos neurosanitarios en Estados Unidos y a nivel internacional. La compañía ofrece el NeuroStar Advanced Therapy System, un tratamiento no invasivo y no sistémico de aplicación ambulatoria para tratar a pacientes adultos con trastorno depresivo mayor. Su NeuroStar Advanced Therapy System utiliza estimulación magnética transcraneal para crear un campo magnético pulsado, de intensidad similar a la de una resonancia magnética, que induce corrientes eléctricas diseñadas para estimular áreas específicas del cerebro asociadas con el estado de ánimo. La compañía vende sus productos a través de su equipo de ventas y atención al cliente a psiquiatras. Neuronetics, Inc. se constituyó en 2001 y tiene su sede central en Malvern, Pensilvania.
| Nombre | NEURONETICS INC. DL-,01 |
| CEO | Daniel L. Reuvers |
| Sede | Malvern,
pa Estados Unidos |
| Sitio web | |
| Sector | Consumo discrecional |
| Industria | Bienes duraderos del hogar |
| Salida a bolsa | 28/06/2018 |
| Empleados | 658 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | STIM |
Frankfurt | NRC.F |
Düsseldorf | NRC.DU |
München | NRC.MU |